Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer

Yundong He, Ji Lu, Zhenqing Ye, Siyuan Hao, Liewei M Wang, Manish Kohli, Donald J. Tindall, Benyi Li, Runzhi Zhu, Liguo Wang, Haojie Huang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Androgen receptor (AR) splice variants (ARVs) are implicated in development of castration-resistant prostate cancer (CRPC). Upregulation of ARVs often correlates with persistent AR activity after androgen deprivation therapy (ADT). However, the genomic and epigenomic characteristics of ARV-dependent cistrome and the disease relevance of ARV-mediated transcriptome remain elusive. Through integrated chromatin immunoprecipitation coupled sequencing (ChIP-seq) and RNA sequencing (RNA-seq) analysis, we identified ARV-preferential-binding sites (ARVPBS) and a set of genes preferentially transactivated by ARVs in CRPC cells. ARVs preferentially bind to enhancers located in nucleosome-depleted regions harboring the full AR-response element (AREfull), while full-length AR (ARFL)-PBS are enhancers resided in closed chromatin regions containing the composite FOXA1-nnnn-AREhalf motif. ARVPBS exclusively overlapped with AR binding sites in castration-resistant (CR) tumors in patients and ARVpreferentially activated genes were up-regulated in abiraterone-resistant patient specimens. Expression of ARV-PBS target genes, such as oncogene RAP2A and cell cycle gene E2F7, were significantly associated with castration resistance, poor survival and tumor progression. We uncover distinct genomic and epigenomic features of ARV-PBS, highlighting that ARVs are useful tools to depict AR-regulated oncogenic genome and epigenome landscapes in prostate cancer. Our data also suggest that the ARV-preferentially activated transcriptional program could be targeted for effective treatment of CRPC.

Original languageEnglish (US)
Pages (from-to)1895-1911
Number of pages17
JournalNucleic Acids Research
Volume46
Issue number4
DOIs
StatePublished - Feb 28 2018

Fingerprint

Androgen Receptors
Castration
Chromatin
Prostatic Neoplasms
Growth
Binding Sites
Epigenomics
Genes
RNA Sequence Analysis
cdc Genes
Nucleosomes
Chromatin Immunoprecipitation
Response Elements
Oncogenes
Transcriptome
Androgens
abiraterone
Neoplasms
Up-Regulation
Genome

ASJC Scopus subject areas

  • Genetics

Cite this

Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. / He, Yundong; Lu, Ji; Ye, Zhenqing; Hao, Siyuan; Wang, Liewei M; Kohli, Manish; Tindall, Donald J.; Li, Benyi; Zhu, Runzhi; Wang, Liguo; Huang, Haojie.

In: Nucleic Acids Research, Vol. 46, No. 4, 28.02.2018, p. 1895-1911.

Research output: Contribution to journalArticle

He, Yundong ; Lu, Ji ; Ye, Zhenqing ; Hao, Siyuan ; Wang, Liewei M ; Kohli, Manish ; Tindall, Donald J. ; Li, Benyi ; Zhu, Runzhi ; Wang, Liguo ; Huang, Haojie. / Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer. In: Nucleic Acids Research. 2018 ; Vol. 46, No. 4. pp. 1895-1911.
@article{847cb86e883341928ee6eba1bf1bfbe0,
title = "Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer",
abstract = "Androgen receptor (AR) splice variants (ARVs) are implicated in development of castration-resistant prostate cancer (CRPC). Upregulation of ARVs often correlates with persistent AR activity after androgen deprivation therapy (ADT). However, the genomic and epigenomic characteristics of ARV-dependent cistrome and the disease relevance of ARV-mediated transcriptome remain elusive. Through integrated chromatin immunoprecipitation coupled sequencing (ChIP-seq) and RNA sequencing (RNA-seq) analysis, we identified ARV-preferential-binding sites (ARVPBS) and a set of genes preferentially transactivated by ARVs in CRPC cells. ARVs preferentially bind to enhancers located in nucleosome-depleted regions harboring the full AR-response element (AREfull), while full-length AR (ARFL)-PBS are enhancers resided in closed chromatin regions containing the composite FOXA1-nnnn-AREhalf motif. ARVPBS exclusively overlapped with AR binding sites in castration-resistant (CR) tumors in patients and ARVpreferentially activated genes were up-regulated in abiraterone-resistant patient specimens. Expression of ARV-PBS target genes, such as oncogene RAP2A and cell cycle gene E2F7, were significantly associated with castration resistance, poor survival and tumor progression. We uncover distinct genomic and epigenomic features of ARV-PBS, highlighting that ARVs are useful tools to depict AR-regulated oncogenic genome and epigenome landscapes in prostate cancer. Our data also suggest that the ARV-preferentially activated transcriptional program could be targeted for effective treatment of CRPC.",
author = "Yundong He and Ji Lu and Zhenqing Ye and Siyuan Hao and Wang, {Liewei M} and Manish Kohli and Tindall, {Donald J.} and Benyi Li and Runzhi Zhu and Liguo Wang and Haojie Huang",
year = "2018",
month = "2",
day = "28",
doi = "10.1093/nar/gkx1306",
language = "English (US)",
volume = "46",
pages = "1895--1911",
journal = "Nucleic Acids Research",
issn = "0305-1048",
publisher = "Oxford University Press",
number = "4",

}

TY - JOUR

T1 - Androgen receptor splice variants bind to constitutively open chromatin and promote abiraterone-resistant growth of prostate cancer

AU - He, Yundong

AU - Lu, Ji

AU - Ye, Zhenqing

AU - Hao, Siyuan

AU - Wang, Liewei M

AU - Kohli, Manish

AU - Tindall, Donald J.

AU - Li, Benyi

AU - Zhu, Runzhi

AU - Wang, Liguo

AU - Huang, Haojie

PY - 2018/2/28

Y1 - 2018/2/28

N2 - Androgen receptor (AR) splice variants (ARVs) are implicated in development of castration-resistant prostate cancer (CRPC). Upregulation of ARVs often correlates with persistent AR activity after androgen deprivation therapy (ADT). However, the genomic and epigenomic characteristics of ARV-dependent cistrome and the disease relevance of ARV-mediated transcriptome remain elusive. Through integrated chromatin immunoprecipitation coupled sequencing (ChIP-seq) and RNA sequencing (RNA-seq) analysis, we identified ARV-preferential-binding sites (ARVPBS) and a set of genes preferentially transactivated by ARVs in CRPC cells. ARVs preferentially bind to enhancers located in nucleosome-depleted regions harboring the full AR-response element (AREfull), while full-length AR (ARFL)-PBS are enhancers resided in closed chromatin regions containing the composite FOXA1-nnnn-AREhalf motif. ARVPBS exclusively overlapped with AR binding sites in castration-resistant (CR) tumors in patients and ARVpreferentially activated genes were up-regulated in abiraterone-resistant patient specimens. Expression of ARV-PBS target genes, such as oncogene RAP2A and cell cycle gene E2F7, were significantly associated with castration resistance, poor survival and tumor progression. We uncover distinct genomic and epigenomic features of ARV-PBS, highlighting that ARVs are useful tools to depict AR-regulated oncogenic genome and epigenome landscapes in prostate cancer. Our data also suggest that the ARV-preferentially activated transcriptional program could be targeted for effective treatment of CRPC.

AB - Androgen receptor (AR) splice variants (ARVs) are implicated in development of castration-resistant prostate cancer (CRPC). Upregulation of ARVs often correlates with persistent AR activity after androgen deprivation therapy (ADT). However, the genomic and epigenomic characteristics of ARV-dependent cistrome and the disease relevance of ARV-mediated transcriptome remain elusive. Through integrated chromatin immunoprecipitation coupled sequencing (ChIP-seq) and RNA sequencing (RNA-seq) analysis, we identified ARV-preferential-binding sites (ARVPBS) and a set of genes preferentially transactivated by ARVs in CRPC cells. ARVs preferentially bind to enhancers located in nucleosome-depleted regions harboring the full AR-response element (AREfull), while full-length AR (ARFL)-PBS are enhancers resided in closed chromatin regions containing the composite FOXA1-nnnn-AREhalf motif. ARVPBS exclusively overlapped with AR binding sites in castration-resistant (CR) tumors in patients and ARVpreferentially activated genes were up-regulated in abiraterone-resistant patient specimens. Expression of ARV-PBS target genes, such as oncogene RAP2A and cell cycle gene E2F7, were significantly associated with castration resistance, poor survival and tumor progression. We uncover distinct genomic and epigenomic features of ARV-PBS, highlighting that ARVs are useful tools to depict AR-regulated oncogenic genome and epigenome landscapes in prostate cancer. Our data also suggest that the ARV-preferentially activated transcriptional program could be targeted for effective treatment of CRPC.

UR - http://www.scopus.com/inward/record.url?scp=85042926375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042926375&partnerID=8YFLogxK

U2 - 10.1093/nar/gkx1306

DO - 10.1093/nar/gkx1306

M3 - Article

VL - 46

SP - 1895

EP - 1911

JO - Nucleic Acids Research

JF - Nucleic Acids Research

SN - 0305-1048

IS - 4

ER -